ABE, N., T. WATANABE, M. SUGIYAMA, H. UCHIMURA, G. CHIAPPETTA, A.
FUSCO u. Y. ATOMI (1999):
Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker.
Cancer Res 59, 1169-1174
ARUN, S. S., W. BREUER u. W. HERMANNS (1996):
Immunohistochemical examination of light-chain expression (lambda/kappa ratio) in canine, feline, equine, bovine and porcine plasma cells.
Zentralbl Veterinarmed A 43, 573-576
BALDASSARRE, G., M. FEDELE, S. BATTISTA, A. VECCHIONE, A. J. KLEIN-SZANTO, M. SANTORO, T. A. WALDMANN, N. AZIMI, C. M. CROCE u. A. FUSCO (2001):
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway.
Proc Natl Acad Sci U S A 98, 7970-7975
BALHORN, R. L., K. A. SKORUPSKI, S. HOK, M. C. BALHORN, T. GUERRERO u.
R. B. REBHUN (2010):
A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas.
Vet Immunol Immunopathol 137, 235-242
BELGE, G., A. MEYER, M. KLEMKE, K. BURCHARDT, C. STERN, W. WOSNIOK, S. LOESCHKE u. J. BULLERDIEK (2008):
Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
Genes Chromosomes Cancer 47, 56-63 BOYCE, K. L. u. B. E. KITCHELL (2000):
Treatment of canine lymphoma with COPLA/LVP.
J Am Anim Hosp Assoc 36, 395-403
BUSSEMAKERS, M. J., W. J. VAN DE VEN, F. M. DEBRUYNE u. J. A. SCHALKEN (1991):
Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis.
Cancer Res 51, 606-611
BUSTIN, M. u. R. REEVES (1996):
High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function.
Prog Nucleic Acid Res Mol Biol 54, 35-100
CHABANNE, L., C. BONNEFONT, J. BERNAUD u. D. RIGAL (2000):
Clinical applications of flow cytometry and cell immunophenotyping to companion animals (dog and cat).
Methods Cell Sci 22, 199-207
CHABANNE, L., T. MARCHAL, C. KAPLANSKI, C. FOURNEL, J. P. MAGNOL, J. C.
MONIER u. D. RIGAL (1994):
Screening of 78 monoclonal antibodies directed against human leukocyte antigens for cross-reactivity with surface markers on canine lymphocytes.
Tissue Antigens 43, 202-205
CHIAPPETTA, G., V. AVANTAGGIATO, R. VISCONTI, M. FEDELE, S. BATTISTA, F. TRAPASSO, B. M. MERCIAI, V. FIDANZA, V. GIANCOTTI, M. SANTORO, A.
SIMEONE u. A. FUSCO (1996):
High level expression of the HMGI (Y) gene during embryonic development.
Oncogene 13, 2439-2446
CHIAPPETTA, G., G. TALLINI, M. C. DE BIASIO, G. MANFIOLETTI, F. J.
MARTINEZ-TELLO, F. PENTIMALLI, F. DE NIGRIS, A. MASTRO, G. BOTTI, M.
FEDELE, N. BERGER, M. SANTORO, V. GIANCOTTI u. A. FUSCO (1998):
Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors:
HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Cancer Res 58, 4193-4198
COBBOLD, S. u. S. METCALFE (1994):
Monoclonal antibodies that define canine homologues of human CD antigens:
summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
Tissue Antigens 43, 137-154
COMAZZI, S., M. E. GELAIN, V. MARTINI, F. RIONDATO, B. MINISCALCO, L.
MARCONATO, D. STEFANELLO u. M. MORTARINO (2011):
Immunophenotype predicts survival time in dogs with chronic lymphocytic leukemia.
J Vet Intern Med 25, 100-106
CRAIG, F. E. u. K. A. FOON (2008):
Flow cytometric immunophenotyping for hematologic neoplasms.
Blood 111, 3941-3967
CULMSEE, K., D. SIMON, R. MISCHKE u. I. NOLTE (2001):
Possibilities of flow cytometric analysis for immunophenotypic characterization of canine lymphoma.
J Vet Med A Physiol Pathol Clin Med 48, 199-206
DATERS, A. T., G. E. MAULDIN, G. N. MAULDIN, E. M. BRODSKY u. G. S. POST (2010):
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Vet Comp Oncol 8, 11-22
DAVIS, B. H., J. T. HOLDEN, M. C. BENE, M. J. BOROWITZ, R. C. BRAYLAN, D.
CORNFIELD, W. GORCZYCA, R. LEE, R. MAIESE, A. ORFAO, D. WELLS, B. L.
WOOD u. M. STETLER-STEVENSON (2007):
2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications.
Cytometry B: Clin Cytom 72 Suppl 1, S5-13
DOBSON, J. M., S. SAMUEL, H. MILSTEIN, K. ROGERS u. J. L. WOOD (2002):
Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs.
J Small Anim Pract 43, 240-246
DORN, C. R., D. O. TAYLOR u. R. SCHNEIDER (1970):
The epidemiology of canine leukemia and lymphoma.
Bibliotheca Haematologica 36, 403-415
DORN, C. R., D. O. TAYLOR, R. SCHNEIDER, H. H. HIBBARD u. M. R. KLAUBER (1968):
Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II.
Cancer morbidity in dogs and cats from Alameda County.
J Natl Cancer Inst 40, 307-318
DUGGAN, P. R., D. EASTON, J. LUIDER u. I. A. AUER (2000): de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis.
Haematologica 89, 686-695
ELOUBEIDI, M. A., S. VARADARAJULU, I. ELTOUM, D. JHALA, D. C. CHHIENG u.
N. C. JHALA (2006):
Transgastric endoscopic ultrasound-guided fine-needle aspiration biopsy and flow cytometry of suspected lymphoma of the spleen.
Endoscopy 38, 617-620
FALDYNA, M., P. SAMANKOVA, L. LEVA, J. CERNY, J. OUJEZDSKA, Z.
REHAKOVA u. J. SINKORA (2007):
Cross-reactive anti-human monoclonal antibodies as a tool for B-cell identification in dogs and pigs.
Vet Immunol Immunopathol 119, 56-62
FALDYNA, M., J. SINKORA, P. KNOTIGOVA, L. LEVA u. M. TOMAN (2005):
Lymphatic organ development in dogs: major lymphocyte subsets and activity.
Vet Immunol Immunopathol 104, 239-247
FEDELE, M., V. FIDANZA, S. BATTISTA, F. PENTIMALLI, A. J. KLEIN-SZANTO, R.
VISONE, I. DE MARTINO, A. CURCIO, C. MORISCO, L. DEL VECCHIO, G.
BALDASSARRE, C. ARRA, G. VIGLIETTO, C. INDOLFI, C. M. CROCE u. A.
FUSCO (2006):
Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice.
Cancer Res 66, 2536-2543
FEDELE, M., F. PENTIMALLI, G. BALDASSARRE, S. BATTISTA, A. J. KLEIN-SZANTO, L. KENYON, R. VISONE, I. DE MARTINO, A. CIARMIELLO, C. ARRA, G.
VIGLIETTO, C. M. CROCE u. A. FUSCO (2005):
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas.
Oncogene 24, 3427-3435
FINN, W. G., L. C. PETERSON, C. JAMES u. C. L. GOOLSBY (1998):
Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry.
Am J Clin Pathol 110, 341-346
FLORY, A. B., K. M. RASSNICK, T. STOKOL, P. V. SCRIVANI u. H. N. ERB (2007):
Stage migration in dogs with lymphoma.
J Vet Intern Med 21, 1041-1047
FRANCO, R., F. ESPOSITO, M. FEDELE, G. LIGUORI, G. M. PIERANTONI, G.
BOTTI, D. TRAMONTANO, A. FUSCO u. P. CHIEFFI (2008):
Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours.
J Pathol 214, 58-64
FUSCO, A. u. M. FEDELE (2007):
Roles of HMGA proteins in cancer.
Nat Rev Cancer 7, 899-910
GARRETT, L. D., D. H. THAMM, R. CHUN, R. DUDLEY u. D. M. VAIL (2002):
Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
J Vet Intern Med 16, 704-709
GEBHARD, D. H. u. P. B. CARTER (1992):
Identification of canine T-lymphocyte subsets with monoclonal antibodies.
Vet Immunol Immunopathol 33, 187-199
GELAIN, M. E., M. MAZZILLI, F. RIONDATO, L. MARCONATO u. S. COMAZZI (2008):
Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry.
Vet Immunol Immunopathol 121, 179-188
GIBSON, D., I. AUBERT, J. P. WOODS, A. ABRAMS-OGG, S. KRUTH, R. D.
WOOD u. D. BIENZLE (2004):
Flow cytometric immunophenotype of canine lymph node aspirates.
J Vet Intern Med 18, 710-717
GLAS, A. M., M. J. KERSTEN, L. J. DELAHAYE, A. T. WITTEVEEN, R. E.
KIBBELAAR, A. VELDS, L. F. WESSELS, P. JOOSTEN, R. M. KERKHOVEN, R.
BERNARDS, J. H. VAN KRIEKEN, P. M. KLUIN, L. J. VAN'T VEER u. D. DE JONG (2005):
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.
Blood 105, 301-307
GREENLEE, P. G., S. E. CALVANO, F. W. QUIMBY u. A. I. HURVITZ (1987):
Investigation of cross-reactivity between commercially available antibodies directed against human, mouse, and rat lymphocyte surface antigens and surface markers on canine cells.
Vet Immunol Immunopathol 15, 285-296
GREENLEE, P. G., D. A. FILIPPA, F. W. QUIMBY, A. K. PATNAIK, S. E. CALVANO, R. E. MATUS, M. KIMMEL, A. I. HURVITZ u. P. H. LIEBERMAN (1990):
Lymphomas in dogs. A morphologic, immunologic, and clinical study.
Cancer 66, 480-490
GRINDEM, C. B., R. L. PAGE, B. E. AMMERMAN u. E. B. BREITSCHWERDT (1998):
Immunophenotypic comparison of blood and lymph node from dogs with lymphoma.
Vet Clin Pathol 27, 16-20
GUERRA, L. L., A. TEIXEIRA-CARVALHO, R. C. GIUNCHETTI, O. A. MARTINS-FILHO, A. B. REIS u. R. CORREA-OLIVEIRA (2009):
Evaluation of the influence of tissue parasite density on hematological and phenotypic cellular parameters of circulating leukocytes and splenocytes during ongoing canine visceral leishmaniasis.
HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma:
preferential expression of HMGA2 in malignant peripheral nerve sheath tumor.
Mod Pathol 18, 1519-1526
JAMAL, S., L. J. PICKER, D. B. AQUINO, R. W. MCKENNA, D. B. DAWSON u. S. H.
KROFT (2001):
Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach.
Am J Clin Pathol 116, 512-526
JOHNSON, A., M. AKERMAN u. E. CAVALLIN-STAHL (1987):
Flow cytometric detection of B-clonal excess in fine needle aspirates for enhanced diagnostic accuracy in non-Hodgkin's lymphoma in adults.
Histopathology 11, 581-590
KAISER, C. I., J. L. FIDEL, M. ROOS u. B. KASER-HOTZ (2007):
Reevaluation of the University of Wisconsin 2-year protocol for treating canine lymphosarcoma.
J Am Anim Hosp Assoc 43, 85-92
KELLER, E. T., E. G. MACEWEN, R. C. ROSENTHAL, S. C. HELFAND u. L. E. FOX (1993):
Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
J Vet Intern Med 7, 289-295
KHANNA, C., E. M. LUND, K. A. REDIC, D. W. HAYDEN, F. W. BELL, E. L.
GOULLAND u. J. S. KLAUSNER (1998):
Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
J Am Vet Med Assoc 213, 985-990
MACDONALD, V. S., D. H. THAMM, I. D. KURZMAN, M. M. TUREK u. D. M. VAIL (2005):
Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
J Vet Intern Med 19, 732-736 MACEWEN, E. G. (1990):
Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.
Cancer Metastasis Rev 9, 125-136
MACEWEN, E. G., A. A. HAYES, R. E. MATUS u. I. KURZMAN (1987):
Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981).
J Am Vet Med Assoc 190, 564-568
MEYER, B., D. KRISPONEIT, C. JUNGHANSS, H. M. ESCOBAR u. J. BULLERDIEK (2007a):
Quantitative expression analysis in peripheral blood of patients with chronic myeloid leukaemia: Correlation between HMGA2 expression and white blood cell count.
Leuk Lymphoma 48, 2008-2013
MEYER, B., S. LOESCHKE, A. SCHULTZE, T. WEIGEL, M. SANDKAMP, T.
GOLDMANN, E. VOLLMER u. J. BULLERDIEK (2007b):
HMGA2 overexpression in non-small cell lung cancer.
Mol Carcinog 46, 503-511
MIYAZAWA, J., A. MITORO, S. KAWASHIRI, K. K. CHADA u. K. IMAI (2004):
Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity.
Cancer Res 64, 2024-2029
MURUA ESCOBAR, H., J. T. SOLLER, A. RICHTER, B. MEYER, S. WINKLER, J.
BULLERDIEK u. I. NOLTE (2005):
"Best friends" sharing the HMGA1 gene: comparison of the human and canine HMGA1 to orthologous other species.
J Hered 96, 777-781
MYERS, N. C., 3RD, A. S. MOORE, W. M. RAND, J. GLIATTO u. S. M. COTTER (1997):
Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
J Vet Intern Med 11, 333-339
NIGEL, P. C. u. M. G. ORMEROD (2000):
Introduction to the principles of flow cytometry.
In: M. G. ORMEROD (Hrsg.): Flow cytometry: a practical approach 3rd Edition, Oxford University Press, Oxford, S. 1-22
ODERO, M. D., F. H. GRAND, S. IQBAL, F. ROSS, J. P. ROMAN, J. L. VIZMANOS, J. ANDRIEUX, J. L. LAI, M. J. CALASANZ u. N. C. CROSS (2005):
Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies.
Leukemia 19, 245-252
OSTRANDER, E. A., F. GALIBERT u. D. F. PATTERSON (2000):
Canine genetics comes of age.
Trends Genet 16, 117-124 OWEN, L. N. (Hrsg.) (1980):
Lymphoid and haematopoietic tissues.
In: TNM Classification of tumours in domestic animals.
World Health Organization (WHO), Geneva, S. 46-47
PATEL, H. S., H. M. KANTARJIAN, C. E. BUESO-RAMOS, L. J. MEDEIROS u. M. A.
HAIDAR (2005):
Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.
Genes Chromosomes Cancer 42, 87-94
PIERANTONI, G. M., V. AGOSTI, M. FEDELE, H. BOND, I. CALIENDO, G.
CHIAPPETTA, F. LO COCO, F. PANE, M. C. TURCO, G. MORRONE, S. VENUTA u. A. FUSCO (2003a):
High-mobility group A1 proteins are overexpressed in human leukaemias.
Biochem J 372, 145-150
PIERANTONI, G. M., B. SANTULLI, I. CALIENDO, F. PENTIMALLI, G.
CHIAPPETTA, N. ZANESI, M. SANTORO, F. BULRICH u. A. FUSCO (2003b):
HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia.
Int J Oncol 23, 363-367
RAMDALL, R. B., G. CAI, T. M. ALASIO u. P. LEVINE (2006):
Fine-needle aspiration biopsy for the primary diagnosis of lymphoproliferative disorders involving the spleen: one institution's experience and review of the literature.
Am J Pathol 149, 775-779
ROGALLA, P., K. DRECHSLER, B. KAZMIERCZAK, V. RIPPE, U. BONK u. J.
BULLERDIEK (1997):
Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade.
Mol Carcinog 19, 153-156
ROMMEL, B., P. ROGALLA, A. JOX, C. V. KALLE, B. KAZMIERCZAK, J. WOLF u.
J. BULLERDIEK (1997):
HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells.
Leuk Lymphoma 26, 603-607
SAKAI, M., I. OTANI, T. WATARI, T. SATO, K. KANAYAMA, A. TAKEUCHI u. A.
HASEGAWA (2003):
Phenotypic analysis of hepatic lymphocytes from healthy dogs.
J Vet Med Sci 65, 157-159
SANTOS, E. S., L. E. RAEZ, J. SALVATIERRA, D. MORGENSZTERN, N.
SHANMUGAN u. G. W. NEFF (2003):
Primary hepatic non-Hodgkin's lymphomas: case report and review of the literature.
Am J Gastroenterol 98, 2789-2793
SANTULLI, B., B. KAZMIERCZAK, R. NAPOLITANO, I. CALIENDO, G.
CHIAPPETTA, V. RIPPE, J. BULLERDIEK u. A. FUSCO (2000):
A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia.
Cancer Genet Cytogenet 119, 70-73
SARHADI, V. K., H. WIKMAN, K. SALMENKIVI, E. KUOSMA, T. SIORIS, J. SALO, A. KARJALAINEN, S. KNUUTILA u. S. ANTTILA (2006):
Increased expression of high mobility group A proteins in lung cancer.
J Pathol 209, 206-212
SIMON, D., S. NARANJO MORENO, J. HIRSCHBERGER, A. MORITZ, B. KOHN, S.
NEUMANN, K. JURINA, S. SCHARVOGEL, C. SCHWEDES, M. REINACHER, M.
BEYERBACH u. I. NOLTE (2008):
Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
J Am Vet Med Assoc 232, 879-885
SIMON, D., I. NOLTE, N. EBERLE, N. ABBREDERIS, M. KILLICH u. J.
HIRSCHBERGER (2006):
Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
J Vet Intern Med 20, 948-954
SÖZMEN, M., S. TASCA, E. CARLI, D. DE LORENZI, T. FURLANELLO u. M.
CALDIN (2005):
Use of fine needle aspirates and flow cytometry for the diagnosis, classification, and immunophenotyping of canine lymphomas.
J Vet Diagn Invest 17, 323-330
STONE, M. S., M. A. GOLDSTEIN u. S. M. COTTER (1991):
Comparison of two protocols for induction of remission in dogs with lymphoma.
J Am Anim Hosp Assoc 27, 315-321 TALLINI, G. u. P. DAL CIN (1999):
HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors.
Adv Anat Pathol 6, 237-246 TARRANT, J. M. (2005):
The role of flow cytometry in companion animal diagnostic medicine.
Vet J 170, 278-288
TESKE, E., P. VAN HEERDE, G. R. RUTTEMAN, I. D. KURZMAN, P. F. MOORE u.
E. G. MACEWEN (1994):
Prognostic factors for treatment of malignant lymphoma in dogs.
J Am Vet Med Assoc 205, 1722-1728
VAIL, D. M., W. C. KISSEBERTH, J. E. OBRADOVICH, F. M. MOORE, C. A.
LONDON, E. G. MACEWEN u. M. A. RITTER (1996):
Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Exp Hematol 24, 807-815
VAIL, D. M. u. E. G. MACEWEN (2000):
Spontaneously occurring tumors of companion animals as models for human cancer.
Cancer Invest 18, 781-792
VALERIUS, K. D., G. K. OGILVIE, C. H. MALLINCKRODT u. D. M. GETZY (1997):
Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
J Am Vet Med Assoc 210, 512-516
WILKERSON, M. J., K. DOLCE, T. KOOPMAN, W. SHUMAN, R. CHUN, L.
GARRETT, L. BARBER u. A. AVERY (2005):
Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Vet Immunol Immunopathol 106, 179-196
WILLMANN, M., L. MULLAUER, A. GUIJA DE ARESPACOCHAGA, M. REIFINGER, I. MOSBERGER u. J. G. THALHAMMER (2009):
Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker.
Vet Immunol Immunopathol 128, 359-365
WINKLER, S., H. M. ESCOBAR, B. MEYER, D. SIMON, N. EBERLE, W.
BAUMGARTNER, S. LOESCHKE, I. NOLTE u. J. BULLERDIEK (2007):
HMGA2 expression in a canine model of prostate cancer.
Cancer Genet Cytogenet 177, 98-102
WINNICKA, A., D. JAGIELSKI, M. HOFFMANN-JAGIELSKA u. R. LECHOWSKI (2002):
Cytometric evaluation of peripheral blood lymphocytes in dogs with lymphoma during chemotherapy.
J Vet Med A Physiol Pathol Clin Med 49, 303-306
WOOD, L. J., M. MUKHERJEE, C. E. DOLDE, Y. XU, J. F. MAHER, T. E. BUNTON, J. B. WILLIAMS u. L. M. RESAR (2000):
HMG-I/Y, a new c-Myc target gene and potential oncogene.
Mol Cell Biol 20, 5490-5502
XU, Y., T. F. SUMTER, R. BHATTACHARYA, A. TESFAYE, E. J. FUCHS, L. J.
WOOD, D. L. HUSO u. L. M. RESAR (2004):
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia.
Cancer Res 64, 3371-3375
YOUNG, N. A., T. I. AL-SALEEM, H. EHYA u. M. R. SMITH (1998):
Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma.
Cancer 84, 252-261
ZEMANN, B. I., A. S. MOORE, W. M. RAND, G. MASON, D. M. RUSLANDER, A. E.
FRIMBERGER, C. A. WOOD, D. A. L'HEUREUX, J. GLIATTO u. S. M. COTTER (1998):
A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
J Vet Intern Med 12, 465-470
ZEPPA, P., G. MARINO, G. TRONCONE, F. FULCINITI, A. DE RENZO, M.
PICARDI, G. BENINCASA, B. ROTOLI, A. VETRANI u. L. PALOMBINI (2004):
Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions.
Cancer 102, 55-65
ZEPPA, P., M. PICARDI, G. MARINO, G. TRONCONE, F. FULCINITI, A. VETRANI, B. ROTOLI u. L. PALOMBINI (2003):
Fine-needle aspiration biopsy and flow cytometry immunophenotyping of lymphoid and myeloproliferative disorders of the spleen.
Cancer 99, 118-127